Hilgers, Reinhard

[["dc.bibliographiccitation.artnumber","R129"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","CRITICAL CARE"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Waeschle, Reiner M."],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Herrmann, Peter"],["dc.contributor.author","Neumann, Peter"],["dc.contributor.author","Quintel, Michael"],["dc.date.accessioned","2018-11-07T11:19:45Z"],["dc.date.available","2018-11-07T11:19:45Z"],["dc.date.issued","2008"],["dc.description.abstract","Introduction The purpose of this study was to assess the relation between glycaemic control and the severity of sepsis in a cohort of patients treated with intensive insulin therapy (IIT). Methods In a prospective, observational study, all patients in the intensive care unit (ICU) (n = 191) with sepsis, severe sepsis or septic shock were treated with IIT (target blood glucose (BG) level 80 to 140 mg/dl instead of strict normoglycaemia). BG values were analysed by calculating mean values, rate of BG values within different ranges, rate of patients experiencing BG values within different levels and standard deviation (SD) of BG values as an index of glycaemic variability. Results The number of patients with hypoglycaemia and hyperglycaemia was highly dependent on the severity of sepsis (critical hypoglycaemia <= 40 mg/dl: sepsis: 2.1%, severe sepsis: 6.0%, septic shock: 11.5%, p = 0.1497; hyperglycaemia: > 140 mg/dl: sepsis: 76.6%, severe sepsis: 88.0%, septic shock: 100%, p = 0.0006; > 179 mg/dl: sepsis: 55.3%, severe sepsis: 73.5%, septic shock: 88.5%, p = 0.0005; > 240 mg/dl: sepsis: 17.0%, severe sepsis: 48.2%, septic shock: 45.9%, p = 0.0011). Multivariate analyses showed a significant association of SD levels with critical hypoglycaemia especially for patients in septic shock (p = 0.0197). In addition, SD levels above 20 mg/dl were associated with a significantly higher mortality rate relative to those with SD levels below 20 mg/dl (24% versus 2.5%, p = 0.0195). Conclusions Patients with severe sepsis and septic shock who were given IIT had a high risk of hypoglycaemia and hyperglycaemia. Among these patients even with a higher target BG level, IIT mandates an increased awareness of the occurrence of critical hypoglycaemia, which is related to the severity of the septic episode."],["dc.identifier.doi","10.1186/cc7097"],["dc.identifier.isi","000261561100017"],["dc.identifier.pmid","18939991"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4949"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55364"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1466-609X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","ISRN Pediatrics"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2012"],["dc.contributor.author","Gross, Oliver"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Görlitz, Anke"],["dc.contributor.author","Gavénis, Karsten"],["dc.contributor.author","Ahmed, Raees"],["dc.contributor.author","Dürr, Ulrike"],["dc.date.accessioned","2019-07-09T11:54:04Z"],["dc.date.available","2019-07-09T11:54:04Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction. Retrospective observational data show that ACE-inhibitor therapy delays renal failure and improves life expectancy in Alport patients with proteinuria. The EARLY PRO-TECT Alport trial assesses the safety and efficacy of early therapy onset with ramipril in pediatric Alport patients.Methods and analysis. This double-blind, randomized, placebo-controlled, multicenter phase III trial (NCT01485978; EudraCT-number 2010-024300-10) includes 120 pediatric patients aged 24 months to 18 years with early stages of Alport syndrome (isolated hematuria or microalbuminuria). From March 2012, up to 80 patients will be randomized 1:1 to ramipril or placebo. In the event of disease progression during 3-year treatment, patients are unblinded and ramipril is initiated, if applicable. Approximately 40 patients receive open-label ramipril contributing to the safety database. Primary endpoints are “time to progression to next disease level” and “incidence of adverse drug events before disease progression.” Treatment effect estimates from the randomized comparison and Alport registry data will be combined in supportive analyses to maximize evidence. Conclusion. Without this trial, ACE inhibitors may become standard off-label treatment in Alport syndrome without satisfactory evidence base. The results are expected to be of relevance for therapy of all pediatric patients with kidney disease, and the trial protocol might serve as a model for other rare pediatric glomerulopathies."],["dc.identifier.doi","10.5402/2012/436046"],["dc.identifier.fs","587146"],["dc.identifier.pmid","22811928"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8396"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60563"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-4703"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","399"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Hoernes, Nina"],["dc.contributor.author","Teucher, Nils"],["dc.contributor.author","Sossalla, Samuel"],["dc.contributor.author","Sehrt, Daniel"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Huenlich, Mark"],["dc.contributor.author","Unsoeld, Bernhard W."],["dc.contributor.author","Geiling, Bianca"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Schwoerer, Harald"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.date.accessioned","2017-09-07T11:47:26Z"],["dc.date.available","2017-09-07T11:47:26Z"],["dc.date.issued","2009"],["dc.description.abstract","Reports on cardiac problems with oral proton pump inhibitors have caused extensive safety reviews by the US Food and Drug Administration. We provide additional data on acute cardiac effects of an intravenous application. Echocardiography was performed in 18 healthy volunteers after administration of a common high-dose regimen of pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h) or placebo. The design included a randomized, double-blind, placebo-controlled cross-over trial. Ejection fraction (%, mean +/- A SE) in the treatment group (placebo group) was 60.7 +/- A 1.1 (61.2 +/- A 1.7) at baseline, and 62.6 +/- A 1.1 (62.1 +/- A 1.9), 64.7 +/- A 1.6 (63.5 +/- A 1.3), 62.6 +/- A 1.6 (61.0 +/- A 1.6) and 63.0 +/- A 1.4 (61.8 +/- A 1.5) at 7.5, 15, 30 and 60 min after bolus application, respectively (p = n.s.). Similarly, no significant changes were found for cardiac output, cardiac index, blood pressure and heart rate. In contrast, gastric pH that was used as a treatment control was significantly increased 60 min after the application of pantoprazole as compared to baseline and to placebo. Pantoprazole as injection is safe in healthy subjects with respect to cardiac contractile function. However, in view of recent reports of negative inotropy of the drug, further studies in heart failure patients are required."],["dc.identifier.doi","10.1007/s00392-009-0012-6"],["dc.identifier.gro","3143105"],["dc.identifier.isi","000267217400008"],["dc.identifier.pmid","19301059"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/583"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","1861-0684"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","293"],["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Weber, Markus"],["dc.contributor.author","Camu, William"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Neuwirth, Christoph"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Benatar, Michael"],["dc.contributor.author","Kuzma-Kozakiewicz, Magdalena"],["dc.contributor.author","Bidner, Helen"],["dc.contributor.author","Blankenstein, Christiane"],["dc.contributor.author","Frontini, Roberto"],["dc.contributor.author","Ludolph, Albert"],["dc.contributor.author","Koch, Jan C."],["dc.date.accessioned","2019-07-09T11:51:01Z"],["dc.date.available","2019-07-09T11:51:01Z"],["dc.date.issued","2019"],["dc.description.abstract","Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Here we describe a clinical trial protocol to repurpose fasudil as a disease-modifying therapy for ALS patients. Methods: ROCK-ALS is a multicenter, double-blind, randomized, placebo-controlled phase IIa trial of fasudil in ALS patients (EudraCT: 2017-003676-31, NCT: 03792490). Safety and tolerability are the primary endpoints. Efficacy is a secondary endpoint and will be assessed by the change in ALSFRS-R, ALSAQ-5, slow vital capacity (SVC), ECAS, and the motor unit number index (MUNIX), as well as survival. Efficacy measures will be assessed before (baseline) and immediately after the infusion therapy as well as on days 90 and 180. Patients will receive a daily dose of either 30 or 60 mg fasudil, or placebo in two intravenous applications for a total of 20 days. Regular assessments of safety will be performed throughout the treatment period, and in the follow-up period until day 180. Additionally, we will collect biological fluids to assess target engagement and evaluate potential biomarkers for disease progression. A total of 120 patients with probable or definite ALS (revised El Escorial criteria) and within 6-18 months of the onset of weakness shall be included in 16 centers in Germany, Switzerland and France. Results and conclusions: The ROCK-ALS trial is a phase IIa trial to evaluate the ROCK-inhibitor fasudil in early-stage ALS-patients that started patient recruitment in 2019."],["dc.identifier.doi","10.3389/fneur.2019.00293"],["dc.identifier.pmid","30972018"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59859"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","974"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Ophthalmic Research"],["dc.bibliographiccitation.lastpage","982"],["dc.bibliographiccitation.volume","64"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Heutelbeck, Astrid"],["dc.contributor.author","Bopp, Silvia"],["dc.contributor.author","Sagebiel, Lise-Lott"],["dc.contributor.author","Eichberg, Silke"],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2022-01-24T07:03:36Z"],["dc.date.available","2022-01-24T07:03:36Z"],["dc.date.issued","2021"],["dc.description.abstract","The aim of this study was to evaluate the prevalence of back pain among German ophthalmologists, to investigate the relationship towards age, gender, various profession-related factors, to correlate localization of pain to subspecialties, and to explore individual therapeutic and coping strategies."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1159/000517574"],["dc.identifier.pmid","34348327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98528"],["dc.language.iso","en"],["dc.relation.eissn","1423-0259"],["dc.relation.issn","0030-3747"],["dc.relation.orgunit","Klinik für Augenheilkunde"],["dc.relation.orgunit","Institut für Medizinische Statistik"],["dc.rights","CC BY-NC 4.0"],["dc.title","Prevalence of Back Pain among German Ophthalmologists"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","795"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","International Urogynecology Journal"],["dc.bibliographiccitation.lastpage","800"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Kociszewski, Jacek"],["dc.contributor.author","Rautenberg, Oliver"],["dc.contributor.author","Kolben, Sebastian"],["dc.contributor.author","Eberhard, Jakob"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Viereck, Volker"],["dc.date.accessioned","2018-11-07T08:41:45Z"],["dc.date.available","2018-11-07T08:41:45Z"],["dc.date.issued","2010"],["dc.description.abstract","This study evaluates the relevance of the tape position and change in shape (tape functionality) under in vivo conditions for mid-term outcome. Changes in the sonographic tension-free vaginal tape (TVT) position relative to the percentage urethral length and the tape-urethra distance were determined after 6 and 48 months in 41 women with stress urinary incontinence. At 48 months, 76% (31/41) of women were cured, 17% (7/41) were improved, and 7% (3/41) were failures. Disturbed bladder voiding was present in 12% (5/41), de novo urge incontinence in 7% (3/41). The median TVT position was at 63% of urethral length. Median tape-urethra distance was 2.7 mm, ranging from 2.9 mm in continent patients without complications to 1.1 mm in those with obstructive complications. Patients with postoperative urine loss had a median distance of 3.9 mm. The tape was stretched at rest and C-shaped during straining in 15 of 41 women (37%) at 48 months (all continent). Patients with this tape functionality at 6 months were also cured at 48 months in 86% of cases (19/22), and only 14% (3/22) showed recurrent incontinence. Mid-term data suggest an optimal outcome if the tape is positioned at least 2 mm from the urethra at the junction of the middle and distal thirds. Patients with optimal tape functionality at 6 months are likely to show mid-term therapeutic success."],["dc.identifier.doi","10.1007/s00192-010-1119-z"],["dc.identifier.isi","000278094200007"],["dc.identifier.pmid","20204326"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19537"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","London"],["dc.relation.issn","0937-3462"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tape functionality: position, change in shape, and outcome after TVT procedure-mid-term results"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]